“Maybe the Democrats would have been more reluctant to shut the government down for a political stunt if they were forced to live like Americans who couldn’t get food stamps, or had their flights cancelled, or didn’t get paid for their work in a federal agency,” Grogan, who oversaw domestic healthcare spending of $1.3 trillion in the last Trump administration, told the Post.
Joe Grogan’s latest op-ed, “Trump’s congressional allies finally move on 340B,” highlights how congressional allies of President Trump are advancing long-awaited reforms to the federal 340B Drug Discount Program, which was designated to help hospitals serve low-income patients but has since ballooned into a system critics say benefits large health systems instead.
John Czwartacki’s latest op-ed, “Trump’s Open Banking Rescue,” argues that President Trump’s renewed “open banking” rule will give consumers control over their financial data again while encouraging innovation in fintech and crypto.
Joe Grogan, in his recent op-ed, “The UK Flirts with Another Attack on U.S. Tech,” warns that the United Kingdom government’s recent consultation, which proposes that the state intervene in setting royalty rates for standard essential patents (SEPs), represents a serious threat to U.S. innovators and global innovation incentives.
In his recent op-ed, “Brazil Is Waging War On American Technology — With China’s Help,” John Czwartacki emphasizes how Brazil is strengthening its ties with China while pushing out American tech companies through unfair digital policies.
The 340B drug-pricing program has ballooned into a $66 billion revenue stream for hospitals, but little of that money actually reaches patients in need. Instead of lowering costs, many hospitals exploit the program for profit while underserved patients continue paying full price.